

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853

Status	RECRUITING
Phase	Phase 2
Sponsor	Pfizer
Enrollment	770 participants

Key Eligibility Criteria

Inclusion (1)

- Healthy and medically stable participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Exclusion (3)

- Tested positive for influenza d5 months (150 days) prior to Visit 1 (Day 1).
- Vaccination with any investigational or licensed influenza vaccine d5 months (150 days) before Visit 1 (Day 1).
- Receipt of antiviral therapies for influenza (eg, Tamiflu) d5 months (150 days) prior to Visit 1 (Day 1).

Locations (15 total)

AMR Clinical, Mobile, Alabama, United States
Diablo Clinical Research, LLC d/b/a Flourish Research, Walnut Creek, California, United States
Clinical Research Consulting, LLC, Milford, Connecticut, United States
... and 12 more locations